RxDoctor Payments Data

Patrick Moriarty, MD

Clinical Pharmacology · Kansas City, KSNPI 1356443675

Payments from drug & device makers

$2,578,083in general payments, 2019–2025

Across 499 payments — averaging $5166.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1M
  • Regeneron$371K
  • Kaneka Medical America LLC$365K
  • Novartis$330K
  • Ionis Pharmaceuticals, Inc.$129K
  • Akcea Therapeutics, Inc.$109K
  • plus $250K from 14 others
$27,932in research payments, 2019–2025

Across 23 payments — averaging $1214.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$12K
  • Novartis$12K
  • Amgen$4K

What the payments were for

  • Consulting fees$275,21756%
  • Speaking & faculty fees$191,49839%
  • Travel & lodging$22,0594%
  • Food & beverage$4,3681%
  • Education$490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical pharmacology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$10,461
Medicare patients
80
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab1,134$835,177
Praluent PenAlirocumab447$282,531
VascepaIcosapent Ethyl272$206,142
Icosapent Ethyl105$43,687
MounjaroTirzepatide33$34,078
NexletolBempedoic Acid48$32,340
NexlizetBempedoic Acid/Ezetimibe30$31,542
OzempicSemaglutide26$24,722
LivaloPitavastatin Calcium19$11,802
Ezetimibe490$11,428
Rosuvastatin Calcium485$6,439
Omega-3 Acid Ethyl Esters28$3,046
Typhim ViTyphoid Vi Polysacch Vaccine12$1,813
Fenofibrate43$1,160
Metformin Hcl84$890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexletol, Nexlizet$49,550$63,88278 claims
Novo NordiskOzempic$20$24,72226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical pharmacology providers in Kansason file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →